CMS Faces New Pressure To Reject Co-Pay Accumulators

By Amy Lotven / October 4, 2022 at 2:11 PM
A coalition of patient and provider groups urges CMS to bar insurers from exempting drug manufacturer coupons from cost-sharing limits in the 2024 exchange rule, and stakeholders also urge HHS to consider the so-called “co-pay accumulators” discriminatory in its final rule on Section 1557 of the Affordable Care Act. Although Medicare bans the use of drug manufacturers’ co-pay coupons, they are allowed in the private market, including Affordable Care Act plans. Insurers say the coupons encourage high drug prices and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.